Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Non-anaemic Iron Deficiency and Iron Supplementation in Girls 15-18 Yrs

17 november 2026 bijgewerkt door: Lund University Hospital

A Cross-sectional Study Analysing P-Ferritin and Psychiatric Symptoms and an Open Trial Evaluating Iron Supplementation in Non-anaemic Iron Deficiency in Girls Aged 15-18 Years With Psychiatric Symptoms

The goal of this observational study is to investigate the prevalence of iron deficiency and the association to psychiatric symptoms in girls 15-18 years attending adolescent mental health services and for those who have an iron deficit offer three months of iron supplementation to evaluate the effect on iron status and on psychiatric symptoms.

THE MAIN QUESTIONS THE STUDY AIMS TO ANSWER IS:

  1. How prevalent is iron deficiency in girls age 15-18 years in adolescent mental health?
  2. Is iron deficiency associated to psychiatric symptoms?
  3. Does iron supplementation with SiderAL- forte, a mild nutritional supplement, improve iron stores and psychiatric symptoms? Is the supplementation well tolerated?
  4. Qualitatively: How do participants describe their understanding of well-being and regarding being informed of low iron stores?How do participants experience iron supplementation and factors that hinder or facilitate treatment?

WHAT IS THE ACTIVITY FOR THE PARTICIPANT?

  • The ongoing treatment at the service is not affected.
  • Blood sampling at the local clinic or with the general practioner and online self report forms are collected at baseline.
  • Participants with iron deficiency will be offered iron supplementation with SiderAL- forte, a mild nutritional supplement for three months.
  • Blood sampling and online self report forms will be collected at 3 and 6 months after start of iron supplementation.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Background Iron deficiency (ID) is common and affect people of all ages, but especially women of reproductive age. About one third of women in North America and 30-40% of adolescent girls in Sweden have ID. Anaemia, i.e. low haemoglobin, is a late consequence of depleted iron stores, and most iron deficiencies still have a haemoglobin within the normal range. Iron is important for transportation and storage of oxygen, but also for neurogenesis, myelination, and neurotransmitter synthesis in the central nervous system. ID typically develops gradually over time, and can remain undiagnosed and untreated. Low serum ferritin is always caused by iron deficiency and is used as an indicator of low iron stores. The WHO cut-off for ID is ferritin levels <15 µg/L. However, this cut-off is argued to be too low, since it is highly suggestive for ID with anaemia but lacks sensitivity for ID without anaemia (IDWA). Ferritin levels of <30 µg/L is suggested as a cut-off for detecting ID among adults, while studies on children and adolescents are scarce. Oral iron supplementation is the first-line treatment for IDWA.

IDWA is associated with psychiatric symptoms such as depression and anxiety, fatigue, inattention, memory difficulties, and disturbed sleep. Low ferritin is associated with ADHD in children. In adolescence, which is a critical period for brain development, IDWA is associated with lower basal ganglia iron content, which in turn is linked to is more depressive symptoms and lower neuropsychological performance. Importantly, the developing adolescent requires more iron because of increased blood volume, rising haemoglobin levels, and increased enzyme production.

Iron supplementation can elevate ferritin levels and improve cognitive performance in women, and furthermore improve aerobic capacity in athletes with IDWA. A recent meta-analysis on iron supplementation for IDWA in children, adolescents, and menstruating women, showed improvements in fatigue, anxiety, physical well-being and short-term memory.

As noted above, studies on IDWA in adolescents are few, particular within Child and Adolescent Mental Health Services (CAMHS). Existing evidence suggests that ferritin levels are lower among children and adolescents attending CAMHS than in the general adolescent population, and one study shows a prevalence approaching 45% for IDWA among inpatient girls. A pilot study on adolescent girls with depression or anxiety disorders found that lower ferritin levels were associated with a higher degree of internalizing symptoms. One small open study (n=19) on iron supplementation for children and adolescents with ferritin <30 µg/L in a CAMHS setting found improved ferritin levels and improvements in depression and sleep. Another small study (n=10) from the same research group found improvements in anxiety, inattention, depression, fatigue, and sleep after iron supplementation for children and adolescents with ferritin <50 µg/L.

In summary, IDWA may be common among adolescent girls attending CAMHS and could contribute to psychiatric symptoms and functional impairment while remaining unrecognised and untreated. However, its prevalence in CAMHS, the extent to which iron status is associated with different psychiatric symptom domains and functioning, and outcomes following iron supplementation in this population remain poorly understood. The present study addresses these gaps by combining large-scale screening and cross-sectional symptom assessment with prospective follow-up of girls with IDWA receiving iron supplementation.

Objectives The primary aim of the cross-sectional study is to estimate the prevalence of iron deficiency without anaemia (IDWA) among girls aged 15-18 years attending CAMHS. Secondary aims are to examine associations between plasma ferritin levels, psychiatric symptoms, and functional impairment, and whether these associations vary by age.

The primary aim of the open trial is to examine changes in psychiatric symptoms and functional impairment following iron supplementation among girls with IDWA, defined as plasma ferritin <30 µg/L. Secondary aims are to assess side effects and adherence, changes in plasma ferritin and haemoglobin, and whether increases in ferritin are associated with improvements in psychiatric symptoms and functioning. An exploratory aim is to identify ferritin levels below which supplementation is associated with greater clinical improvement.

Study design The first phase is a cross-sectional study screening for plasma ferritin levels in girls aged 15-18 years who have had at least one visit at a CAMHS clinic in Region Halland during the preceding year. Based on administrative data, we estimate that around 1500 patients will be eligible and that around 750 will consent. Participants will be assessed with blood samples and web-based self-reporting scales on psychiatric symptoms.

The second phase is an open trial of iron supplementation for three months in participants with a plasma ferritin below 30 µg/L at baseline, with follow-ups at three, six and twelve months after baseline.

Participants Inclusion criteria for the cross-sectional study are girls aged 15-18 who have had at least one visit at a CAMHS clinic in Region Halland during the preceding year, with no exclusion criteria. Patients will be identified through a scanning of the outpatient administrative files. They will be contacted by text message with brief information about the study and an invitation to participate. There will be a link to a homepage with participant information. Patients who have not responded will receive an invitation by letter with participant information. After consent, the web-based questionnaire regarding symptoms will be sent electronically. When questionnaires are filled in, the blood tests will be issued. The participant will be informed not to have the blood drawn if ill by an acute infection but to wait until the infection has abated. Results of laboratories will be sent by text messages including the following suggestions: 1) referral to general practitioner in case of a) anaemia (haemoglobin <116 mg/mL), b) ferritin >200 µg/L, or c) CRP >30 mg/mL; 2) invited to a second blood test after three or more weeks if C-Reactive Protein (CRP) 2-30 mg/mL; and 3) invited to participate in the open trial of iron supplementation if ferritin <30 µg/L and CRP <2 mg/mL.

Inclusion criteria for the open trial is participants from the open trial with plasma ferritin <30 µg/L and CRP <2 mg/mL. Exclusion criteria for the open trial are: a) ongoing iron supplementation, b) Hb <116 mg/mL, and c) CRP >2 mg/mL.

Treatment Participants in the open study will be provided free of charge nutritional supplementation with iron (SiderAL Forte) to be taken once daily for three months. SiderAL Forte utilises a liposomal technology which increases bioavailability and possibly reduces side-effects. SiderAL Forte contains 30 mg of iron and 70 mg of vitamin C to enhance uptake. It appears to have similar effects as higher doses of ferrous iron. Participants will be offered support regarding side-effects through text messages or phone.

The regular treatment at the CAP clinic will continue fully separated from the open trial. Clinicians will receive a notice that iron supplementation is ongoing, and that secure handling of the iron related to risk of intentional overdosing is a responsibility of the clinician in line with the safety precautions of the other medications that are part of the treatment at the clinic.

Statistics A cross-sectional sample of 750 participants will provide good precision for estimating the prevalence of IDWA. Assuming a prevalence of 30%, the expected 95% confidence interval is approximately 27-33%. Across plausible prevalence estimates ranging from 10% to 60%, the corresponding margin of error is approximately ±2-4 percentage points. This sample also provides 80% power to detect correlations as small as r = 0.10 at an alpha level of 0.05. An open-trial sample of 250 participants provides approximately 88% power to detect a small within-group change (Cohen's d = 0.20) from baseline to 6 months. Recruitment will therefore continue until 750 participants have been included in the cross-sectional study.

For the open trial, we aim to include 250 participants with IDWA. A sample of this size provides approximately 88% power to detect a small within-group change of Cohen's d = 0.20 from baseline to 6 months at an alpha level of 0.05. Recruitment to the cross-sectional study will continue until 750 participants have been included, with an anticipated open-trial sample of approximately 250 participants.

Demographic data will be summarised using descriptive statistics. In the cross-sectional study, the prevalence of IDWA will be estimated using ferritin thresholds of <15, and <30 µg/L, with corresponding 95% confidence intervals. Associations between ferritin levels, psychiatric symptoms, and functional impairment will be examined using correlations and regression models adjusting for relevant covariates, including age.

In the open trial, missing data will first be addressed using multiple imputation by chained equations. The imputation model will include variables from the primary analyses as well as relevant auxiliary variables that predict missingness or the variables being imputed. The number of imputations will be selected to provide stable estimates and may be increased depending on the amount of missing information.

Changes in psychiatric symptoms and functional impairment following iron supplementation will then be analysed using linear mixed-effects models with repeated measures. Models will include time as a fixed effect and a participant-level random intercept to account for within-person correlation. Analyses will estimate mean changes over time with 95% confidence intervals. Models will be fitted separately within each imputed dataset and estimates pooled using Rubin's rules.

Secondary analyses will examine whether within-person increases in ferritin are associated with within-person improvements in psychiatric symptoms and functional impairment. Changes in ferritin and haemoglobin will also be described, together with side effects and adherence to supplementation.

Missingness will be summarised by participant and assessment point, and associations between missingness, baseline characteristics, and previously observed outcomes will be examined to assess the plausibility of the missing-at-random assumption. Sensitivity analyses based on observed data and, if warranted, analyses examining departures from the missing-at-random assumption will be conducted.

Exploratory analyses will examine whether baseline ferritin predicts symptom trajectories by testing ferritin-by-time interactions and will explore baseline ferritin thresholds associated with clinically meaningful symptom improvement. These analyses will be considered exploratory and interpreted using effect estimates and 95% confidence intervals rather than confirmatory hypothesis testing.

Qualitative interviews Individual semi-structured interviews will be conducted approximately four months after treatment initiation, corresponding to one month after the planned three-month supplementation period. This timing allows participants to reflect on receiving their blood test results and their experiences during and after supplementation. Interviews will be conducted by a researcher experienced in qualitative interviewing who is not involved in the participant's clinical care. T. The interviews will take place either in an undisturbed setting or via a video platform, depending on the participant's preference. The interviews are expected to last approximately 30-60 minutes, will be audio-recorded following informed consent, and transcribed verbatim.

The interview guide will cover participants' well-being and everyday life; experiences of receiving and understanding their blood test results; the meaning, if any, of these results for their understanding of their own well-being; experiences of taking iron supplements, including factors that facilitate or hinder supplementation; perceived changes or lack of change in well-being and everyday life; and experiences of information, communication and support from healthcare professionals. Open-ended questions and follow-up prompts will encourage participants to describe their experiences in their own words and provide concrete examples, without presupposing that the test results or supplementation had any particular significance for them.

Studietype

Ingrijpend

Inschrijving (Geschat)

250

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Halland County
      • Halmstad, Halland County, Zweden, 30290

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

15 jaar tot 18 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Attending the Child and Adolescent Mental Health Services at Region Halland, Sweden during December 2025-November 2026;
  • Plasma-Ferritin below 30 microgram/L

Exclusion Criteria:

  • Haemoglobin below 116 g/L
  • Ongoing iron supplementation/treatment

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Dietary supplement with iron

SiderAL-Forte contains 30 mg of ferrous iron and 70 mg of vitamin C

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The PROMIS paediatric fatigue scale
Tijdsspanne: one week

Change from baseline to three (primary) and six (secondary) months for The PROMIS paediatric fatigue scale is a 10 item scale evaluating symptoms of fatigue in children and adolescents, with responses on a five point Likert scale ranging from 1 (never) to 5 (almost always) with total score ranging from 10-50. Total scores are converted to T-scores. A higher score is worse. The PROMIS paediatric fatigue scale is translated into Swedish, validated in a Swedish CAP setting and has shown acceptable psychometric properties.

one week

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The Revised Child Anxiety and Depression Scale (RCADS-30)
Tijdsspanne: one week

Change from baseline to follow-up at 3 and 6 months in the Revised Child Anxiety and Depression Scale, a youth self-report questionnaire for ages 8-18 years with items on a four-point Likert scale from 0 (none) to 3 (always) and subscales including: separation anxiety disorder, social phobia, generalized anxiety disorder, panic disorder, obsessive compulsive disorder, and low mood (major depressive disorder). Total scores ranges from 0 to 90. A higher score is worse. RCADS-30 is an abbreviated version, where all the original scales are retained, with good psychometric properties.

one week
The ADHD Self-Report Scale for Adolescents (ASRS)
Tijdsspanne: one week

ASRS is an abbreviated 18-item questionnaire aligning with DSM-5 with a four point Likert scale from 0 (none) to 3 (always). Total score ranges from 0 to 54, higher is worse. It has shown good psychometric properties.

one week
Irritability (IDAS-II)
Tijdsspanne: one week

The Irritability subscale comprises with five items from the Inventory of Depression and Anxiety Symptoms scored from 1 (not at all) to 5 (extremely). Total score ranges from 5 to 25. A higher score is worse.

one week
Functioning (UFID)
Tijdsspanne: one week

The Uppsala scale of Functional Impairment in Daily life to capture how mental health problems and mental disorders affect global functioning across five core domains: family relationships, self-care and daily routines, schoolwork, peer relationships, and leisure activities. Each domain is rated on a five-point Likert scale from = (functioning well) to 4 (not functioning at all), yileding a total score ranging from 0 to 20, with higher scores indicating rgeater impairment.

one week
KIDSCREEN
Tijdsspanne: one week

Kidscreen-10 is a self-rating scale on health related quality of life with ten items ranging from 1 (not at all/never) to 9 (extremely/always). Total score ranges from 10 through 90 with higher scores indicating a better quality of life.

one week
Ferritin
Tijdsspanne: periprocedural

Ferritin is an iron binding protein and the best non-invasive marker for iron deficiency. It detects iron defiency before the development of anemia. WHO standards has a cut off at 15 micrograms/liter for iron defiency while recent consensus suggests a cut off at 30 15 micrograms/liter. Lower is worse. Ferritin is also an acute phase reactant and increased ferritin can thus result from a concomitant inflammation. To control for this false negative result, another acute phase reactant (C-reactive protein) is also analyzed and deemed to be normal (less than 2 gram/liter) for the ferritin value to be indicative of iron stores.

periprocedural
Haemoglobin
Tijdsspanne: periprocedural

Haemoglobin is an iron-containing protein in the red blood cells, to transport oxygen. Haemoglobin synthesis requires iron. A normal range for adolescent girls is set to 116 through 149 gram/liter while anaemia is determined by a value less than 116 gram/liter.

periprocedural
Side effect form (P-SEC)
Tijdsspanne: three months (since started taking supplement)

Paediatric side effect checklist is custom made with six items from the Swedish package insert of iron tablets. It is scored o a four point Likert scale ranging from 0 (no problems) to 3 (severe problems/not acceptable). Each item is presented separately with no total scale values.

three months (since started taking supplement)
Adherence (MARS-5)
Tijdsspanne: three months (since started taking supplement)

Medication Adherence Report Scale is a five item instrument for self-reported adherence to medication. It consists of five items rated on a five-point Likert scale from 1 (never) to 5 (always) with higher scores producing a total score ranging from 5 to 25. Higher scores indicate a greater self-reported medicatioin adherence.

three months (since started taking supplement)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Onderzoekers

  • Studie stoel: Matti Cervin, Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Sweden.
  • Hoofdonderzoeker: Hakan Jarbin, MD, PhD, Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Sweden; Child and Adolescent Psychiatric Clinic, Region Halland, Sweden
  • Studie stoel: Sara Marie Larsson, Clinical biochemist, PhD, Department of Clinical Chemistry, Region Halland, Varberg/Halmstad Sweden; Department of Clinical Sciences, Pediatrics, Lund University, Lund, Sweden
  • Studie stoel: Ingrid Larsson, RN, PhD, School of Health and Welfare, Department of Health and Nursing, Halmstad University, Halmstad, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of clinical sciences, Section of Rheumatology, Lund University, Lund, Sweden

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

28 februari 2028

Studie voltooiing (Geschat)

28 februari 2029

Studieregistratiedata

Eerst ingediend

2 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

17 november 2026

Eerst geplaatst (Werkelijk)

19 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

17 november 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 2026-04227-01

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Data will not be made public in line with the ethical approval. However, researchers will, upon reasonable request, get access to the pseudonymized data file.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .